Skip to main navigation Skip to search Skip to main content

Acceptability of advanced Controlled Human Infection Models: The case of a pneumococcal challenge in people living with HIV and mycobacterial challenge with Bacillus Calmette Guerin in Malawi

  • on behalf of the Malawi Accelerated Research in Vaccines by Experimental and Laboratory Systems (MARVELS) consortium
  • , Anthony E. Chirwa
  • , Charity Gunda
  • , Shalom Songolo
  • , Edna Nsomba
  • , Neema Toto
  • , Lumbani Makhaza
  • , Mphatso Mailboy
  • , Clara Ngoliwa
  • , Linda Chamtunga
  • , Modesta Reuben
  • , Chikondi Chakwiya
  • , Pemphero Liwonde
  • , Andrew Sigoloti
  • , Evaristar Kudowa
  • , Godwin Tembo
  • , Ben Morton
  • , Bridgette Galafa
  • , Faith Thole
  • , Lorensio Chimgoneko
  • Brenald Dzonzi, Vitumbiko Nkhoma, Edward Mangani, Mphatso Mayuni, Alfred Muyaya, Fanny Kapakasa, Morrison P. Kamanga, Tiyamika Nthandira, Diana Mwaipaya, Nengie Chirwa, Ndaziona P.K. Banda, Marc Y.R. Henrion, Tarsizio Chikaonda, Kondwani C. Jambo, Blessings Kapumba, Stephen B. Gordon, Anna C.T. Gordon, Deborah Nyirenda
  • Malawi-Liverpool-Wellcome Trust Clinical Research Programme
  • University of Edinburgh
  • University of Bristol
  • PATH
  • Immbio
  • University College London
  • Liverpool School of Tropical Medicine
  • Radboud University Nijmegen
  • Department of Clinical Sciences
  • University of Srathclyde

Research output: Contribution to journal › Article › peer-review

Abstract

Controlled Human Infection Models (CHIM) in which volunteers are experimentally exposed to pathogens are used to study pathogenesis and down select among treatment and vaccine candidates. Scientifically, CHIM studies are best conducted among at-risk populations in which the infection is endemic, and who are likely to benefit from new interventions tested. Ethically, the perspectives of these communities should be carefully considered in designing such research. CHIM studies are often conducted among healthy adults, but we wished to understand study participant's and community views on conducting CHIM studies in groups other than healthy adults, particularly people living with HIV (PLHIV). We also wished to explore community perceptions of a tuberculosis CHIM (TB CHIM), initially using Bacillus Calmette Guerin (BCG) as a safe intermediate step. We conducted fourteen focus group discussions (FGD) and eight in-depth interviews (IDI) among a wide range of stakeholders including participants, health workers, community advisory groups, religious leaders and medical opinion leaders in Malawi. Discussions and interviews were recorded, transcribed and analysed using thematic and framework analysis. Four themes were described in the data, showing engaged stakeholder acceptance of CHIM studies, and confidence in the research practice and motivation. In the specific examples discussed in this work at-risk populations specifically PLHIV and complex pathogens specifically TB-CHIM, there was concern for safety, proper consent and community consultation. In addition, cultural views on gender roles in Malawi, tissue sampling and residential stays for research study were discussed. Overall, there was support for CHIM among PLHIV, and CHIM working through a BCG CHIM towards safe TB CHIM in future. Appropriate safety caveats and regulatory measures were suggested. Advice on wide, public awareness campaign methods was offered to researchers.

Original languageEnglish
Article numbere0006236
JournalPLOS Global Public Health
Volume6
Issue number8
DOIs
Publication statusPublished - 18 Aug 2026

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Acceptability of advanced Controlled Human Infection Models: The case of a pneumococcal challenge in people living with HIV and mycobacterial challenge with Bacillus Calmette Guerin in Malawi'. Together they form a unique fingerprint.

Cite this